Oklahoma,
J&J to wrap up first trial over opioid crisis
Send a link to a friend
[July 15, 2019]
By Nate Raymond
(Reuters) - Oklahoma's attorney general is
expected on Monday to urge a judge to find Johnson & Johnson responsible
for flooding the market with painkillers and fueling the U.S. opioid
epidemic, as the first trial in nationwide litigation over the drug
crisis comes to an end.
|
Lawyers for Attorney General Mike Hunter and J&J are set to deliver
closing arguments in state court in Norman, Oklahoma following six
weeks of testimony from current and former J&J executives and
victims of the epidemic.
The case is one of more than 2,000 actions by state and local
governments accusing drug manufacturers of contributing to an
epidemic linked to a record 47,600 opioid overdose deaths in 2017,
according to the U.S. Centers for Disease Control and Prevention.
The Oklahoma case is being closely watched by plaintiffs in other
opioid lawsuits, particularly in 1,900 cases pending in Ohio brought
largely by cities and counties against J&J and other companies.
The federal judge overseeing that litigation has been pushing for a
settlement ahead of an October trial.
Oklahoma says that starting in the 1990s, New Jersey-based J&J used
misleading marketing to push doctors to prescribe more opioids.
The state claims that J&J, which sold the painkillers Duragesic and
Nucynta, marketed the opioids as "safe and effective for everyday
pain" and downplayed their addictive qualities.
The state has accused J&J of acting as the "kingpin" behind the
epidemic and says it was motivated to boost prescriptions not only
because it sold painkillers but because it also grew and imported
raw materials opioid manufacturers like OxyContin maker Purdue
Pharma LP used.
[to top of second column] |
J&J denies the allegations. Its lawyers have argued that its
products made up a small share of opioids prescribed in Oklahoma and
carried U.S. Food and Drug Administration-approved labels that
warned of the addictive risks.
The company says the state lacks evidence linking J&J's marketing to
doctors writing unwarranted opioid prescriptions or that it caused
the epidemic.
The company also has said that the state is seeking to stretch the
bounds of a public nuisance statute in order to force J&J to pay up
to $17.5 billion to remedy the crisis.
Cleveland County District Judge Thad Balkman, who will hear the
arguments, will rule at a later date.
Purdue and Teva Pharmaceutical Industries Ltd were originally also
defendants in the case. Purdue reached a $270 million settlement
with the state in March and Teva settled for $85 million in June.
Both deny wrongdoing.
(Reporting by Nate Raymond in Boston; editing by Noeleen Walder and
Steve Orlofsky)
[© 2019 Thomson Reuters. All rights
reserved.] Copyright 2019 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
|